NCT07158177 Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity
| NCT ID | NCT07158177 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Cataract and IOL Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-10-01 with a primary completion date of 2026-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Retrospective, comparative, interventional, randomized, single-center study, contralateral (the patient's 2 eyes will be implanted: 1 CPO and the other APO) Patients presenting for cataract surgery with a request for presbyopia correction and managed as part of routine clinical practice. The main aim of the study is to demonstrate that contrast sensitivity is better with the Clareon PanOptix (CPO) intraocular lens (IOL) compared with the AcrySof PanOptix (APO) IOL 3 months after implantation.
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years of age * Patients presenting for cataract surgery in routine clinical practice and eligible for multifocal IOL implantation (toric and non-toric) * Patients with grade 2/3 cataract density and comparable visual acuity in both eyes * Patient with a pregnancy test (negative pregnancy test), if applicable * Patient with signed consent to participate in the study * Patient affiliated to a social security scheme or entitled beneficiary Exclusion Criteria: * Children \< 18 years of age * Pregnancy or breast-feeding in progress or planned during the study. * History of anterior (cornea, anterior chamber, sulcus) or posterior (uveal, vitreoretinal) segment pathology, including retinal vascular occlusive disease, retinal detachment or peripheral retinal laser photocoagulation, AMD, glaucoma. * Any inflammation of the anterior or posterior segment, whatever the etiology, and/or history of any disease with intraocular inflammatory repercussions. * Clinically significant corneal pathology (epithelial, stromal and/or endothelial) that could have an impact on visual results. * Clinically significant moderate or severe dry eye that could affect study measurements. * History of intraocular or corneal surgery (refractive or trauma-related). * Presence or history of amblyopia or monofixation syndrome. * Subjects with conditions that increase the risk of zonular disruption during the phacoemulsification procedure that may affect the centration or postoperative orientation of the IOL. * Any other planned eye surgery, including, but not limited to, limbal relaxing incision (LRI)/astigmatic keratotomy and laser refractive surgery (LASIK). * Irregular astigmatism identified by corneal topography * Patients under guardianship, curatorship or safeguard of justice, as well as pregnant or breast-feeding women (article L1121-5 of the CSP).1.1 * Patient under AME
Contact & Investigator
Dominique MONNET, MD, PhD
PRINCIPAL INVESTIGATOR
Université Paris Cité, Faculté de Santé / UFR de médecine
Frequently Asked Questions
Who can join the NCT07158177 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cataract and IOL Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07158177 currently recruiting?
Yes, NCT07158177 is actively recruiting participants. Contact the research team at dominique.monnet@aphp.fr for enrollment information.
Where is the NCT07158177 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT07158177 clinical trial?
NCT07158177 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Dominique MONNET, MD, PhD at Université Paris Cité, Faculté de Santé / UFR de médecine. The trial plans to enroll 40 participants.